Rapamycin + Everolimus + Prednisone
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Comparative Study
Conditions
Comparative Study, Immunosuppressive Agents
Trial Timeline
Jul 1, 2008 → Jun 1, 2010
NCT ID
NCT01183247About Rapamycin + Everolimus + Prednisone
Rapamycin + Everolimus + Prednisone is a approved stage product being developed by Novartis for Comparative Study. The current trial status is completed. This product is registered under clinical trial identifier NCT01183247. Target conditions include Comparative Study, Immunosuppressive Agents.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01183247 | Approved | Completed |